Key Highlights

  • Net loss before noncontrolling interest was $51.8 million, compared with $35.8 million a year earlier.
  • Cash, cash equivalents and marketable securities totaled $141.9 million at September 30, 2026.
  • The pivotal eGFR slope topline readout remains on track for the second quarter of 2027.
  • The company expects its cash to support operations into mid-2027.

ProKidney Corp. (NASDAQ:PROK) reported financial results for the third quarter ended September 30, 2026, and provided Business highlights on November 12, 2026. The Winston-Salem, North Carolina company is a late-stage cell therapy developer focused on chronic kidney disease. The quarter featured progress in enrollment for its pivotal PROACT 1 study, new data presented at the American Society of Nephrology's Kidney Week, and a larger quarterly loss than a year earlier.

Pivotal Program and Enrollment

Chief Executive Bruce Culleton said PROACT 1 is advancing toward full enrollment and that the pivotal eGFR slope topline readout remains on track for the second quarter of 2027. The company said a planned interim analysis in the first quarter of 2027 will include more than 500 patients, up from 470, driven by accelerated recruitment in mid-2026.

At Kidney Week 2026, ProKidney presented eight abstracts. The company said the new data further strengthen the mechanistic and clinical evidence for rilparencel, and it hosted a key opinion leader event to recap the findings and discuss the product's potential role in advanced CKD and type 2 diabetes.

Financial Results and Liquidity

The net loss before noncontrolling interest was $51.8 million, compared with $35.8 million in the third quarter of 2025. The company did not provide a detailed expense breakdown in its headline section, so the drivers of the increase are not identified in the summary.

Cash, cash equivalents and marketable securities totaled $141.9 million at September 30, 2026, compared with $181.6 million at June 30, 2026. The company said that balance supports operations into mid-2027, a period that overlaps with the expected pivotal readout.

The quarter's cash decline from $181.6 million at June 30 to $141.9 million at September 30 is a useful reference point for the company's spending pace. Combined with the stated runway into mid-2027, it shows how much the company's funding depends on the timing of its trial milestones.

Sector Context

Cell therapy approaches to chronic kidney disease are at an early stage of clinical development, and the field has few approved disease-modifying treatments. Pivotal trials in kidney disease often use eGFR slope as a key endpoint because it tracks the rate of kidney function decline over time.

ProKidney's readout timing places its data in a period when many investors and clinicians will be looking at the broader CKD market. The company's emphasis on mechanistic evidence reflects the need to show how its therapy works as well as whether it slows decline in patients.

Risks and What Lies Ahead

The company's cash runway ends in mid-2027, shortly after the expected pivotal readout. That timing means the company will need to plan for additional financing or other sources of funds if the readout is delayed or if further spending is required.

Upcoming developments to monitor include the interim analysis in the first quarter of 2027, full enrollment in PROACT 1 and the eGFR slope topline data. Regulatory feedback after the readout will shape the next steps for rilparencel.

The company's emphasis on the interim analysis and full enrollment shows that the next few quarters are organized around a sequence of data points. A favorable readout would move the company toward regulatory discussions, while a disappointing result would raise questions about the program's path. The release does not specify the regulatory steps that would follow a readout.

Final Word

The third quarter shows ProKidney advancing its pivotal program and presenting more data, while its quarterly net loss increased and its cash balance declined from June. The company's pivotal eGFR slope readout in the second quarter of 2027 is the central event for its timeline, and its runway into mid-2027 leaves little Margin around that date. The results and the company's financing plans will be the key items to follow.